Schwarz Pharma wins OK for Parkinson's patch

As expected, Germany's Schwarz Pharma won FDA approval to market its Neupro patch for Parkinson's disease. "Neupro is the first transdermal patch approved for the treatment of symptoms of Parkinson's disease," said the FDA in a statement. The patch delivers the therapy rotigotine for the brain disease. Rotigotine is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning. The system is applied to the skin once a day and provides rotigotine continuously to the body for 24 hours.

- check out the release for more information

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.